Home / Market News / $HIMS
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Evercore ISI Raises Price Target for Hims & Hers Health

Nov 13, 2026, 7:07 PM UTC · Primary ticker $HIMS

Evercore ISI has increased its price target for Hims & Hers Health (HIMS) stock from $24 to $27, while keeping an 'in-line' rating. This indicates a slightly more optimistic view on the company's valuation by the analyst firm, which could provide a modest positive sentiment for investors.

Evercore ISI has raised its price target for Hims & Hers Health (HIMS) from $24 to $27, signaling an improved outlook on the company's future valuation. While the 'in-line' rating suggests the firm doesn't see it as a strong buy or sell, the increased price target reflects a more positive assessment of its market position and financial trajectory. This news primarily affects current and potential investors in HIMS, potentially leading to a short-term positive bump in stock price due to increased analyst confidence. Long-term implications depend on whether the company's performance justifies this higher valuation. A key opportunity for traders is to capitalize on any immediate positive sentiment, though the 'in-line' rating suggests limited upside from this news alone.

$HIMS positive Analyst price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.